Het Nederlandse biofarmaceutische bedrijf Pantarhei Bioscience heeft met ingang van januari 2019 haar Chief Operating Officer (COO) Yvette Zimmerman benoemd tot Chief Executive Officer (CEO). De oprichter en voormalig CEO van Pantarhei, Herjan Coelingh Bennink, is trots op zijn opvolgster: “Yvette is een zeer ervaren ontwikkelaar van nieuwe geneesmiddelen, gemotiveerd door wat echt belangrijk is voor zieke mensen en wat wetenschappelijk vernieuwend is.”

Pantarhei bestaat nu 18 jaar en heeft in die tijd meer dan 220 patenten ingediend. Oorspronkelijk was Pantarhei gericht op het ontwikkelen van nieuwe geneesmiddelen op het gebied van Women’s Health. Sinds de oprichting van het dochterbedrijf Pantarhei Oncology in 2014, is de focus verlegd naar nieuwe hormonale behandelingen van kanker, met name borst- en prostaatkanker.

Lees verder: Persbericht Nieuwe CEO Pantarhei Bioscience

Pantarhei Oncology announces favorable efficacy results of the fetal estrogen Estetrol in women with advanced breast cancer.

Press release Pantarhei Oncology December 6 2018

On 3 May 2018 the first patient has been randomized in the phase IIA clinical study assessing efficacy and safety of the fetal estrogen estetrol (E4) in prostate cancer patients. The study is a double blind, randomised, placebo-controlled multi-center study in prostate cancer patients treated with an LHRH agonist. In total 60 patients will be enrolled at eight centers in the Netherlands.

The main objectives of this study are to evaluate the additional effect of E4 on testosterone (T) suppression (total T as well as free T) by the LHRH agonist as well as the prevention and treatment of hypoestrogenic side effects due to the concomitant suppression of estrogens.

 

 

On Friday December 1, 2017, the CEO of Pantarhei Herjan Coelingh Bennink lectured during the session: Breast cancer risk from hormonal treatment.

The title of the lecture qualified by the organisers as countercurrent was: “Estrogens protect against breast cancer and can be used in selected cases for the treatment of breast cancer”.

For more information please read the abstract: Abstract COGI Estrogens and Breast Cancer

Symposium on Sexuality / Women’s Sexual Dysfunction
Friday October 20, 2017

Chairpersons: Ali Kubba and Josep Perello

Programme:

Rossella E. Nappi:
Sexual symptoms at menopause: are they all women’s dysfunction?

Johannes Bitzer:
Sexual health care for cancer patients.

Rik HW van Lunsen:
The Amsterdam multifacettel approach of sexual pain disorders aiming at restoring sexual pleasure.

Herjan J.T. Coelingh Bennink:
Improvement of sexual function during pill use by normalising free testosterone levels.

For more information please read the abstract: Abstract ESG Barcelona Oct 2017